Results 181 to 190 of about 436,511 (214)
Some of the next articles are maybe not open access.
Dengue infection and advances in dengue vaccines for children
The Lancet Child & Adolescent Health, 2019Dengue viruses are endemic in most tropical and subtropical countries where they produce disease ranging from a mild fever to a severe, potentially fatal vascular permeability syndrome. We reviewed the status of development and testing in children of three vaccines designed to protect against the four dengue viruses.
Scott B, Halstead, Leonila F, Dans
openaire +2 more sources
Introducing dengue vaccine: Implications for diagnosis in dengue vaccinated subjects
Vaccine, 2016Diagnosis of dengue virus infections is complicated by preference for different diagnostic tests in different post onset days of illness and the presence of multiple serotypes leading to secondary and tertiary infections. The sensitivity of the most commonly employed diagnostic assays such as anti dengue IgM capture (MAC) ELISA and non structural ...
openaire +2 more sources
Advancing dengue vaccine development
Science, 2017Insights into the natural history of dengue virus infection guide vaccine ...
Mark B, Feinberg, Rafi, Ahmed
openaire +2 more sources
Advances in dengue vaccine development
Human Vaccines, 2009Dengue viruses are the most important arboviruses causing human disease. Expansion of the disease in recent decades to include more geographical areas of the world, an appreciation of the disease burden and market potentials have spurred a flurry of activity in the development of vaccines to combat dengue viruses.
Kanakatte, Raviprakash +3 more
openaire +2 more sources
This chapter offers an overview of dengue vaccines that have advanced to clinical trials, addressing the intricate challenges in their development. It details the complexities of the dengue virus, including its four serotypes and the phenomenon of antibody-dependent enhancement (ADE), which significantly impacts vaccine design.
openaire +2 more sources
openaire +2 more sources
Current issues in dengue vaccination
Current Opinion in Infectious Diseases, 2013Dengue is a global health problem and of concern to travelers and deploying military personnel, with development and licensure of an effective tetravalent dengue vaccine a public health priority. The recent performance of the lead dengue vaccine in a phase 2b efficacy trial underscores dengue vaccine development challenges.
Stephen J, Thomas, Timothy P, Endy
openaire +2 more sources
Dengue vaccines: progress and challenges
Current Opinion in Immunology, 2011With several dengue vaccine candidates progressing through clinical trials, several options for controlling this disease appear feasible. This would represent a major achievement and reflect decades of research and development activities. The challenges associated with the limited understanding of protective responses and those factors which determine ...
Beth-Ann G, Coller, David E, Clements
openaire +2 more sources
Dengue Virus Vaccine Development
2014Dengue virus (DENV) is a significant cause of morbidity and mortality in tropical and subtropical regions, causing hundreds of millions of infections each year. Infections range from asymptomatic to a self-limited febrile illness, dengue fever (DF), to the life-threatening dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS).
Lauren E, Yauch, Sujan, Shresta
openaire +2 more sources
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2006
Dengue is an expanding health problem. About two-fifths of the world population are at risk for acquiring dengue with 50-100 million cases of acute febrile illness yearly including about 500,000 cases of DHF/DSS. No antiviral drugs active against the flavivirus exist. Attempts to control mosquito vector has been largely unsuccessful.
Sriluck, Simasathien +1 more
openaire +1 more source
Dengue is an expanding health problem. About two-fifths of the world population are at risk for acquiring dengue with 50-100 million cases of acute febrile illness yearly including about 500,000 cases of DHF/DSS. No antiviral drugs active against the flavivirus exist. Attempts to control mosquito vector has been largely unsuccessful.
Sriluck, Simasathien +1 more
openaire +1 more source